About
COUR Pharmaceuticals develops nanoparticle therapies that deliver disease-specific antigens or allergens to antigen-presenting cells in the spleen and liver through natural, non-inflammatory phagocytic pathways to modulate the immune system.
Explore COUR Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.